Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; and to design, engineer, and develop therapeutics that combine tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies to access previously undruggable tissue and cell types, and target underlying genetic drivers of diseases. In addition, it develops muscle programs, which focuses on the treatment of facioscapulohumeral muscular dystrophy, Duchenne muscular dystrophy, muscle atrophy, and Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is based in La Jolla, California.
IPO Year: 2020
Exchange: NASDAQ
Website: aviditybiosciences.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/13/2025 | $70.00 | Buy | Citigroup |
| 3/12/2025 | $72.00 | Outperform | BMO Capital Markets |
| 3/7/2025 | $70.00 | Sector Outperform | Scotiabank |
| 12/20/2024 | $72.00 | Buy | H.C. Wainwright |
| 11/26/2024 | $67.00 | Outperform | RBC Capital Mkts |
| 9/24/2024 | $59.00 | Buy | Goldman |
| 8/28/2024 | $63.00 | Overweight | Barclays |
| 5/3/2024 | $40.00 | Buy | BofA Securities |
| 3/14/2024 | $60.00 | Overweight | Cantor Fitzgerald |
| 5/22/2023 | $20.00 | In-line → Outperform | Evercore ISI |
On track to deliver key regulatory updates for del-brax and topline data from dose escalation cohorts in the FORTITUDE™ trial in the second quarter Positive topline del-zota data further supports first BLA submission at year end 2025 – continues to highlight reproducibility and consistency across three late-stage clinical trials for DMD44, DM1 and FSHD Executing on global commercial infrastructure development and on track with preparations for first potential commercial launch in U.S. in 2026 Strong balance sheet supports execution across three late-stage clinical programs and commercial launch preparations with cash runway into mid-2027 SAN DIEGO, May 8, 2025 /PRNewswire/ -- Avidity Biosc
SAN DIEGO, May 6, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will participate in a fireside chat during the following investor conference: Bank of America Securities 2025 Health Care Conference on Tuesday, May 13, 2025, at 3:00 p.m. PT / 6:00 p.m. ETLive webcast of the event, up-to-date event details and an archived replay will be available on the "Events and Presentations" page in the
SAN DIEGO, April 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on April 20, 2025, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 263,000 shares of its common stock and 131,450 restricted stock units ("RSUs") to thirty-three (33) new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan (the "2022 Inducement Plan"). The awards were granted as inducements material to the empl
Del-desiran first-ever investigational treatment for DM1 to receive Orphan Drug designation in Japan SAN DIEGO, April 8, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the Japan Ministry of Health, Labour and Welfare (MHLW) has granted Orphan Drug designation (ODD) to delpacibart etedesiran (del-desiran) for the treatment of myotonic dystrophy type 1 (DM1), an investigational treatment designed to address the root cause of DM1, an underrecognized, progressive and often fatal neuromuscular disease with no approved therapie
SAN DIEGO, April 1, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will participate in a fireside chat during the following investor conference: 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025, at 3:00 p.m. ETLive webcast of the event, up-to-date event details and an archived replay will be available on the "Events and Presentations" page in the "Investors" secti
Del-brax FORTITUDE biomarker cohort designed for potential accelerated approval; plan to share regulatory update in Q2 2025 Regulatory alignment on global Phase 3 del-brax trial design and study initiation anticipated in Q2 2025 Plan to present topline data from FORTITUDE dose escalation cohorts in Q2 2025 On track to be first globally approved drug for FSHD SAN DIEGO, March 31, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the completion of enrollment in the biomarker cohort in the Phase 1/2 FORTITUDE™ clinical trial of delpa
SAN DIEGO, March 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on March 20, 2025, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 101,200 shares of its common stock and 50,900 restricted stock units ("RSUs") to sixteen (16) new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan (the "2022 Inducement Plan"). The awards were granted as inducements material to the employees
On track for year end 2025 BLA submission for accelerated approval of 5 mg/kg every six weeks of del-zota in DMD44 Consistent favorable safety and tolerability across del-zota dose cohorts Plan to present functional data in fourth quarter of 2025 Investor and analyst webcast event today at 8:00 a.m. ET SAN DIEGO, March 17, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced positive del-zota topline data from the Phase 1/2 EXPLORE44® trial in people living with Duchenne muscular dystrophy amenable to exon 44 skipping (DMD44) demons
Aravindhan Veerapandiyan, MD, Associate Professor of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children's Hospital and EXPLORE44® trial investigator, will present topline del-zota data from Phase 1/2 EXPLORE44 trial at 2025 MDA Clinical & Scientific Conference in Dallas, Texas Avidity to host investor and analyst webcast event March 17, 2025, at 8:00 a.m. ET Key opinion leaders to participate in Avidity sponsored industry forum event "Advancing RNA Therapeutics", March 17, 2025, at 7:00 a.m. CT/8:00 a.m. ET SAN DIEGO, March 12, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therap
SAN DIEGO, Feb. 28, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced it is joining the global community of patients, caregivers, families and healthcare providers to build broader awareness of rare diseases, including rare neuromuscular diseases, and the urgent need for more approved treatments for many of these conditions in support of Rare Disease Day®. "Rare Disease Day represents an important opportunity for al
4 - Avidity Biosciences, Inc. (0001599901) (Issuer)
4 - Avidity Biosciences, Inc. (0001599901) (Issuer)
4 - Avidity Biosciences, Inc. (0001599901) (Issuer)
4 - Avidity Biosciences, Inc. (0001599901) (Issuer)
4 - Avidity Biosciences, Inc. (0001599901) (Issuer)
4 - Avidity Biosciences, Inc. (0001599901) (Issuer)
4 - Avidity Biosciences, Inc. (0001599901) (Issuer)
4 - Avidity Biosciences, Inc. (0001599901) (Issuer)
4 - Avidity Biosciences, Inc. (0001599901) (Issuer)
4 - Avidity Biosciences, Inc. (0001599901) (Issuer)
– Industry veteran to serve as independent director, strengthening the board and bringing extensive leadership, executive and governance experience to Cartography as it builds out its oncology platform and pipeline - Cartography Biosciences, Inc., an oncology company advancing a pipeline of antibody therapeutics that more precisely target tumors, today announced the appointment of Troy E. Wilson, Ph.D., J.D., as an independent director. Dr. Wilson, a 25-year veteran of the biopharma industry, is President, CEO and co-founder of Kura Oncology (NASDAQ:KURA) and has served as chairman of its Board of Directors since it was founded in 2014. "We are delighted to have attracted a true industry
SAN DIEGO, Aug. 5, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the appointment of John B. Moriarty, Jr., J.D., as Chief Legal Officer and Corporate Secretary, effective immediately. With almost 30 years of industry experience, Mr. Moriarty brings extensive legal expertise and a proven track record of successfully guiding leading global biotech companies through transformational growth. Mr. Moriarty succeeds Joh
Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (NASDAQ:RNA), as an independent member of its Board of Directors. Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum's board. Ms. Boyce has extensive expertise in global pharmaceut
SAN DIEGO, May 15, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the appointment of Simona Skerjanec, M.Pharm, MBA to its board of directors. Ms. Skerjanec brings nearly three decades of global experience in the pharmaceutical industry with a strong track record in developing and launching therapies, as well as shaping corporate strategy to deliver transformative treatments to people living with serious diseases.
STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.Hans Schikan has been a member of the Board since 2018 and is a leader in rare disease drug development and strategy. He was previously CEO of Prosensa (NASDAQ:RNA), a company developing therapies for rare diseas
SAN DIEGO, Feb. 29, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced its support for Rare Disease Day®, highlighting the importance of bringing awareness to the devastating impact rare diseases have on patients, families and caregivers worldwide. "Today, on Rare Disease Day, we are proud to join the global community in raising awareness for people living with rare diseases," said Sarah Boyce, president and chief exe
Avidity is on-track to initiate global Phase 3 HARBOR™ trial of AOC 1001 for DM1 in mid-2024 Company to share first-look at long-term efficacy and safety data from MARINA-OLE™ trial in people living with DM1 at MDA Clinical & Scientific Conference and via webcast on March 4, 2024 Avidity to report data from clinical programs for people living with FSHD and DMD44 later this year SAN DIEGO, Feb. 28, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the fourth quarter and year ended December 31, 2023, and highli
Avidity plans to initiate global Phase 3 HARBOR™ trial of AOC 1001 for DM1 mid-2024 Company to report data from all three ongoing clinical programs in 2024 -- AOC 1001 data for DM1 in Q1, AOC 1020 data for FSHD in Q2, and AOC 1044 data for DMD44 in 2H -- Avidity to advance wholly-owned and partnered cardiology programs toward clinical development Avidity appoints Eric B. Mosbrooker as Chief Strategy Officer SAN DIEGO, Jan. 5, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced its 2024 corporate priorities and catalysts for the next
SAN DIEGO, Feb. 23, 2022 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the appointment of Steve Hughes, M.D. as chief medical officer. Dr. Hughes has over 20 years of experience building and leading clinical development and medical affairs teams at prominent biopharmaceutical companies. "Steve brings a unique combination of extensive experience in the RNA field as well as a deep understanding of rare disease drug deve
LA JOLLA, Calif., Aug. 25, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA) a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the appointment of experienced global commercial and operations executive, Eric Mosbrooker to its board of directors. Mr. Mosbrooker is an industry leader with expertise in building global commercial organizations, as well as marketing, market access, distribution, and compliance. The company also announced the departure of Roderick Wong, M.
Citigroup initiated coverage of Avidity Biosciences with a rating of Buy and set a new price target of $70.00
BMO Capital Markets initiated coverage of Avidity Biosciences with a rating of Outperform and set a new price target of $72.00
Scotiabank initiated coverage of Avidity Biosciences with a rating of Sector Outperform and set a new price target of $70.00
H.C. Wainwright initiated coverage of Avidity Biosciences with a rating of Buy and set a new price target of $72.00
RBC Capital Mkts initiated coverage of Avidity Biosciences with a rating of Outperform and set a new price target of $67.00
Goldman initiated coverage of Avidity Biosciences with a rating of Buy and set a new price target of $59.00
Barclays initiated coverage of Avidity Biosciences with a rating of Overweight and set a new price target of $63.00
BofA Securities initiated coverage of Avidity Biosciences with a rating of Buy and set a new price target of $40.00
Cantor Fitzgerald initiated coverage of Avidity Biosciences with a rating of Overweight and set a new price target of $60.00
Evercore ISI upgraded Avidity Biosciences from In-line to Outperform and set a new price target of $20.00
10-Q - Avidity Biosciences, Inc. (0001599901) (Filer)
8-K - Avidity Biosciences, Inc. (0001599901) (Filer)
DEFA14A - Avidity Biosciences, Inc. (0001599901) (Filer)
DEF 14A - Avidity Biosciences, Inc. (0001599901) (Filer)
8-K - Avidity Biosciences, Inc. (0001599901) (Filer)
8-K - Avidity Biosciences, Inc. (0001599901) (Filer)
8-K - Avidity Biosciences, Inc. (0001599901) (Filer)
144 - Avidity Biosciences, Inc. (0001599901) (Subject)
S-8 - Avidity Biosciences, Inc. (0001599901) (Filer)
10-K - Avidity Biosciences, Inc. (0001599901) (Filer)
Discussions with the FDA ongoing as Avidity submits emerging AOC 1001 data from the MARINA trial AOC 1001 continues to be generally well tolerated; Avidity provides more information on the rare serious adverse event in a single participant that led to the partial clinical hold AOC 1001 top-line safety and functional data to be presented at the American Academy of Neurology (AAN) Annual Meeting on April 27, 2023 Avidity to hold a webcast/conference call today at 8:00 a.m. ET/5:00 a.m. PT SAN DIEGO, March 30, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates
Participants currently enrolled in MARINA and MARINA-OLE™ trials may continue to be treated with AOC 1001 Avidity received Investigational New Drug (IND) clearance for FSHD and DMD studies from FDA; programs now advancing into the clinic Company to host investor webcast today at 8:30 a.m. ET / 5:30 a.m. PT SAN DIEGO, Sept. 27, 2022 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on new participant enrollment in the Phase 1/2 MARINA™ clinical trial of A
SC 13G/A - Avidity Biosciences, Inc. (0001599901) (Subject)
SC 13G/A - Avidity Biosciences, Inc. (0001599901) (Subject)
SC 13G - Avidity Biosciences, Inc. (0001599901) (Subject)
SC 13G/A - Avidity Biosciences, Inc. (0001599901) (Subject)
SC 13G/A - Avidity Biosciences, Inc. (0001599901) (Subject)
SC 13G/A - Avidity Biosciences, Inc. (0001599901) (Subject)
SC 13G - Avidity Biosciences, Inc. (0001599901) (Subject)
SC 13G/A - Avidity Biosciences, Inc. (0001599901) (Subject)
SC 13D/A - Avidity Biosciences, Inc. (0001599901) (Subject)
SC 13G - Avidity Biosciences, Inc. (0001599901) (Subject)